395 related articles for article (PubMed ID: 17032148)
1. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological therapy of Paget's and other metabolic bone diseases.
Hosking D
Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
[TBL] [Abstract][Full Text] [Related]
4. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
5. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
[TBL] [Abstract][Full Text] [Related]
6. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
Krane SM
Nat Clin Pract Rheumatol; 2006 Apr; 2(4):186-7. PubMed ID: 16932682
[No Abstract] [Full Text] [Related]
7. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
8. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
9. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
[TBL] [Abstract][Full Text] [Related]
11. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.
Siris ES; Chines AA; Altman RD; Brown JP; Johnston CC; Lang R; McClung MR; Mallette LE; Miller PD; Ryan WG; Singer FR; Tucci JR; Eusebio RA; Bekker PJ
J Bone Miner Res; 1998 Jun; 13(6):1032-8. PubMed ID: 9626635
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
[TBL] [Abstract][Full Text] [Related]
13. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
Siris ES; Lyles KW; Singer FR; Meunier PJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
[TBL] [Abstract][Full Text] [Related]
14. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
[TBL] [Abstract][Full Text] [Related]
15. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
[TBL] [Abstract][Full Text] [Related]
16. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
[TBL] [Abstract][Full Text] [Related]
17. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.
Reid IR; Lyles K; Su G; Brown JP; Walsh JP; del Pino-Montes J; Miller PD; Fraser WD; Cafoncelli S; Bucci-Rechtweg C; Hosking DJ
J Bone Miner Res; 2011 Sep; 26(9):2261-70. PubMed ID: 21638319
[TBL] [Abstract][Full Text] [Related]
18. Determinants of remission of Paget's disease of bone.
Patel S; Stone MD; Coupland C; Hosking DJ
J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
[TBL] [Abstract][Full Text] [Related]
19. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
20. Biochemical assessment of Paget's disease of bone.
Shankar S; Hosking DJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]